Distinguished in Acute Lymphoblastic Leukemia (ALL)

Ralf C. Bargou

Wuerzburg, BY, DE 
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Ralf Bargou practices in Wuerzburg, Germany. Mr. Bargou is rated as a Distinguished expert by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Leukemia, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 23 articles in the study of Acute Lymphoblastic Leukemia (ALL).

Gender
Male

Locations

Wuerzburg, BY, Germany
Other Locations
Munich, BY, Germany
Erlangen, BY 91054, Germany
Berlin, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The GDFATHER-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The GDFATHER-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
Enrollment Status: Terminated
Publish Date: July 10, 2023
Intervention Type: Drug
Study Drug: GEM3PSCA
Study Phase: Phase 1
View 1 Less Clinical Trial

96 Total Publications

Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.
Journal: JCO precision oncology
Published: August 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bargou's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile